NCT06646666View on ClinicalTrials.gov

ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

June 1, 2027

Study Completion Date

December 1, 2027

Conditions
B-cell Non Hodgkin Lymphoma
Interventions
DRUG

All-trans retinoic acid

10mg，tid，po (After apheresis and continued until post-infusion)

DRUG

zanubrutinib

160mg，bid，po (prior to apheresis and continued until post-infusion)

RADIATION

radiotherapy

If the patient's specific lesions are suitable for radiotherapy

DRUG

CAR-T

CAR-T cell therapy

DRUG

PD-1 inhibitor

IV 200 mg on D1, Q3W

Trial Locations (1)

Unknown

Department of Hematology, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER